New NIH-funded memory drug moves into Phase 1 clinical study

(Source – National Institutes of Health)

Collaboration between NIH and Tetra Discovery Partners leads to development of treatment that may affect cognition.

An experimental drug that may improve memory is now being tested in a Phase 1 safety trial. The compound, BPN14770, was developed by Tetra Discovery Partners, with support from the NIH Blueprint Neurotherapeutics Network, a program designed to facilitate the discovery and development of novel neurological treatments. It is the first compound funded by the program to reach a Phase 1 clinical trial. Read more…


Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s 
 validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or